Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 1

Baseline characteristic of eligible articles.

Studies	Cases		Effect (CR + PR)		Chemotherapeutic drugs		Age (year)		ADR	Immune function
	T	C	T (CR/PR)	C (CR/PR)	T	C	T	C
Wang and Liu, 2015 [27]	32	32	21 (3/18)	12 (1/11)	OXA + CF + 5-FU + CKI (12 ml/d)	OXA + CF + 5-FU	21–72	23–71	1, 3, 5, 6, 7	—
Tao and Xu, 2013 [29]	74	74	46 (14/32)	23 (7/16)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	49–74	49–74	1, 3, 5, 8, 10, 11, 12	—
Li et al., 2015 [31]	26	26	23 (16/7)	20 (13/7)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	45–68	45–70	—	IL-2, TNF-α, INF-γ
Kang et al., 2015 [33]	52	52	19 (1/18)	13 (0/13)	OXA + CF + 5-FU + CKI (20 ml/d)	OXA + CF + 5-FU			2, 4, 6	CD3+, CD4+, CD4+/CD8+, NK
Gao and Feng, 2014 [34]	40	40	27 (8/19)	12 (3/9)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	31–73	30–75	1, 3, 4, 5, 8, 9	—
R. R. Li and H. S. Li, 2015 [35]	35	35	22 (2/20)	15 (1/14)	IV + CF + 5-FU + CKI (15 ml/d)	IR + CF + 5-FU	41–63	42–64	1, 4, 5, 6, 7	—
Liu, 2014 [36]	52	52	46 (21/25)	36 (17/19)	OXA + CF + 5-FU + CKI (20 ml/d)	OXA + CF + 5-FU	36–78	38–76	—	—
Qi, 2016 [37]	36	36	22 (7/15)	10 (3/7)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	42–68	43–60	1, 3	—
Zheng et al., 2011 [38]	36	20	21 (3/18)	8 (1/7)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	40–69	40–69	1, 3, 4, 5, 11	CD3+, CD4+, CD8+, CD4+/CD8+
Xu, 2014 [39]	30	30	24 (12/12)	18 (8/10)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU	45–78	43–78	—	—
Wang et al., 2015 [40]	33	33	21 (3/18)	12 (1/11)	OXA + CF + 5-FU + CKI (15 ml/d)	OXA + CF + 5-FU			1, 3, 5, 6, 7	—
Ren et al., 2014 [41]	60	60	42 (14/28)	40 (8/32)	OXA + CF + CKI (12 ml/d)	OXA + CF	37–73	33–76	2, 4, 6, 7,	—
Fang and Zhang, 2012 [42]	36	36	30 (20/10)	21 (9/12)	OXA + CF + 5-FU + CKI (12 ml/d)	OXA + CF + 5-FU	17–70	18–72	1, 8	—
Xiang and Liu, 2016 [43]	39	38	18 (7/11)	15 (3/12)	OXA + R + CKI (20 ml/d)	OXA + RA	29–75	31–73	1, 3, 5, 6, 11, 12	—

Note. T: Compound Kushen Injection combined with chemotherapeutic drugs group; C: chemotherapeutic drugs alone group; CR: complete remission; PR: partial remission; 1: nausea and vomiting; 2: myelosuppression; 3: leukopenia; 4: digestive tract reaction (Diarrhea); 5: thrombocytopenia; 6: liver injury; 7: renal injury; 8: neurotoxicity; 9: anaemia.; 10: oral mucositis; 11: hypochromia; 12: peripheral phlebitis.